Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CANF Can Fite Biofarma

Post-Mkt 07-13 16:13:02 EDT

3.26

+0.01

+0.31%

盘后3.23

-0.03-0.92%

16:12 EDT

High3.29	Low3.15	Vol87.79K
Open3.25	D1 Closing3.25	Amplitude4.31%
Mkt Cap6.98M	Tradable Cap6.86M	Total Shares2.14M
T/O285.24K	T/O Rate4.17%	Tradable Shares2.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CANF","market":"US","secType":"STK","nameCN":"Can Fite Biofarma","latestPrice":3.26,"timestamp":1783972800000,"preClose":3.25,"halted":0,"volume":87789,"hourTrading":{"tag":"盘后","latestPrice":3.23,"preClose":3.26,"latestTime":"16:12 EDT","volume":86,"amount":278.02000019999997,"timestamp":1783973549429,"change":-0.03,"changeRate":-0.009202,"amplitude":0.009202},"delay":0,"changeRate":0.0030769230769230114,"floatShares":2105000,"shares":2142546,"eps":-1791.0249,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"07-13 16:13:02 EDT","open":3.25,"high":3.29,"low":3.15,"amount":285240.9286272,"amplitude":0.043077,"askPrice":3.54,"askSize":100,"bidPrice":2.95,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1791.0249,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783987200000},"marketStatusCode":4,"adr":0,"adrRate":300,"listingDate":1384837200000,"exchange":"AMEX","adjPreClose":3.25,"preHourTrading":{"tag":"盘前","latestPrice":3.27,"preClose":3.25,"latestTime":"09:18 EDT","volume":7548,"amount":25439.542947600003,"timestamp":1783948682396,"change":0.02,"changeRate":0.006154,"amplitude":0.04},"postHourTrading":{"tag":"盘后","latestPrice":3.23,"preClose":3.26,"latestTime":"16:12 EDT","volume":86,"amount":278.02000019999997,"timestamp":1783973549429,"change":-0.03,"changeRate":-0.009202,"amplitude":0.009202},"volumeRatio":0.256518},"requestUrl":"/m/hq/s/CANF","defaultTab":"news","newsList":[{"id":"2649814629","title":"Can-Fite BioPharma Completes Enrollment in Phase 3 Study of Potential Plaque Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2649814629","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649814629?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:46","pubTimestamp":1783338411,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  has completed enrolment of the first 247 patients in its pivotal phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis, the company said Monday.The study has now reached a pre-specified interim stage under a protocol agreed with both the US Food and Drug Administration and the European Medicines Agency, the company said.Results from the study are expected during Q4 2026 or Q1 2027, the company said.Shares of the company were up 2.3% in recent premarket trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649307626","title":"Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2649307626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649307626?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:15","pubTimestamp":1783336542,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced completion of enrolment of the first 247 patients in its Phase 3 study evaluating Piclidenoson for the treatmen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-enrolls-247-patients-in-piclidenoson-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-enrolls-247-patients-in-piclidenoson-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504855","title":"Can-fite Biopharma Price Target Raised to $8.00/share from $5.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648504855?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:09","pubTimestamp":1782990540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings(END) Dow Jones NewswiresJuly 02, 2026 07:09 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648067385","title":"Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2648067385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648067385?lang=en_us&edition=fundamental","pubTime":"2026-07-02 18:00","pubTimestamp":1782986415,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Can-Fite BioPharma (CANF) to $8 from $5 and keeps a Buy rating on the shares. The company reporte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-price-target-raised-to-8-from-5-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-price-target-raised-to-8-from-5-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648816540","title":"Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2648816540","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648816540?lang=en_us&edition=fundamental","pubTime":"2026-07-02 01:11","pubTimestamp":1782925891,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CANF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646352888","title":"Can-Fite Secures Japanese Patent for Namodenoson's Anti-Obesity Tech; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2646352888","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646352888?lang=en_us&edition=fundamental","pubTime":"2026-06-26 19:54","pubTimestamp":1782474877,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  has secured a patent in Japan covering the use of certain adenosine receptor agonists, including its Namodenoson lead drug candidate, for inducing fat loss and treating obesity and related metabolic disorders, the company said Friday.The company has already secured patent protection for the technology in the US, Canada, Australia and other major regions, it said.Can-Fite shares were up 18% in premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CANF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635990759","title":"Can-Fite Biopharma Raised to Buy From Hold by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2635990759","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635990759?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:24","pubTimestamp":1778707440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 17:24 ET (21:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290707","title":"Can-Fite Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290707","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634290707?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:46","pubTimestamp":1778582760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 06:46 ET (10:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312873","title":"Can-Fite BioPharma completes enrollment in Piclidenoson study","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312873","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312873?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:37","pubTimestamp":1774870638,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-completes-enrollment-in-piclidenoson-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-completes-enrollment-in-piclidenoson-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622863932","title":"Press Release: Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2622863932","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622863932?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:27","pubTimestamp":1774531620,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, March 26, 2026  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for the year ended December 31, 2025 and early 2026.Phase 2a study in pancreatic cancer met its primary endpoint of safety in heavily pretreated patients. The study continues to follow patients for overall survival, with data maturing over time; currently more than 30% of patients are alive at last data cut-off.Motti Farbstein Can-Fite's CEO&CFO stated: \"The past months have marked a period of significant progress for Can-Fite, highlighted by encouraging clinical signals across multiple indications and continued expansion of our intellectual property portfolio. Notably, clinical observations in adva","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4097","LU2065732104.USD","BK4139","CANF","PRGS","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242190","title":"Can-Fite BioPharma announces Israeli patent allowance for namodenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242190","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242190?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:50","pubTimestamp":1773748214,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that the Israeli Patent Office has allowed its patent application No. 284463, titled “An A3 Adenosine Receptor ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-announces-israeli-patent-allowance-for-namodenoson-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-announces-israeli-patent-allowance-for-namodenoson-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616071551","title":"Can-Fite Shares Rise After Pancreatic Cancer Study Meets Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616071551","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616071551?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:36","pubTimestamp":1772638593,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  shares were up over 90% in recent Wednesday trading after the company said its phase 2a study of  namodenoson in patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.The study, which enrolled 20 patients who had received one or more prior lines of therapy, showed that namodenoson was very well tolerated, and no new safety signals were identified, it said.Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off, the company said.Price: 9.62, Change: +4.62, Percent Change: +92.40","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616596215","title":"Amex Halt  News Pending Lst 10.400000","url":"https://stock-news.laohu8.com/highlight/detail?id=2616596215","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616596215?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:43","pubTimestamp":1772635400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nAQN2LORS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610630357","title":"Can-Fite BioPharma receives Canadian patent allowance for namodenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2610630357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610630357?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:15","pubTimestamp":1770639327,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-receives-canadian-patent-allowance-for-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-receives-canadian-patent-allowance-for-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604118867","title":"Can-Fite completes patient enrollment in Phase 2a study of Namodenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2604118867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604118867?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:10","pubTimestamp":1768911021,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that patient enrollment has been completed in its Phase 2a pancreatic cancer clinical trial of Namodenoson. The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-completes-patient-enrollment-in-phase-2a-study-of-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-completes-patient-enrollment-in-phase-2a-study-of-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.canfite.com","stockEarnings":[{"period":"1week","weight":-0.1688},{"period":"1month","weight":0.1525},{"period":"3month","weight":0.113},{"period":"6month","weight":-0.215},{"period":"1year","weight":-0.843},{"period":"ytd","weight":-0.1875}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.230769,"avgChangeRate":-0.076322},{"month":2,"riseRate":0.615385,"avgChangeRate":0.008528},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.089458},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.059668},{"month":5,"riseRate":0.461538,"avgChangeRate":-0.016529},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.022002},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.023292},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.032507},{"month":9,"riseRate":0.333333,"avgChangeRate":0.032332},{"month":10,"riseRate":0.25,"avgChangeRate":-0.068864},{"month":11,"riseRate":0.583333,"avgChangeRate":0.063516},{"month":12,"riseRate":0.230769,"avgChangeRate":-0.10464}],"exchange":"AMEX","name":"Can Fite Biofarma","nameEN":"Can Fite Biofarma","securityTypeName":"DR","adrRate":"1:300"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Can Fite Biofarma,CANF,Can Fite Biofarma股票,Can Fite Biofarma股票老虎,Can Fite Biofarma股票老虎国际,Can Fite Biofarma行情,Can Fite Biofarma股票行情,Can Fite Biofarma股价,Can Fite Biofarma股市,Can Fite Biofarma股票价格,Can Fite Biofarma股票交易,Can Fite Biofarma股票购买,Can Fite Biofarma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction